Analysis Ranks Top-Performing Immunotherapy for Cervical Cancer

Cervical cancer is the fourth most common malignancy in women, and standard treatments can fail in up to 30% of patients. A new class of drugs, called immune checkpoint inhibitors (ICIs), offers hope by helping the body's own immune system fight cancer.

With several ICIs available, choosing the most effective one has been a challenge. To solve this, scientists performed a network meta-analysis, a sophisticated method for comparing treatments by pooling data from five major randomised trials involving over 3,300 patients.

The results point to a clear leader. For both locally advanced and metastatic cervical cancer, the addition of pembrolizumab to standard care like chemoradiotherapy ranked highest. It consistently delivered better overall survival and progression-free survival. While this evidence strongly supports the preferential use of pembrolizumab, the authors highlight that direct head-to-head trials are still needed to confirm these important findings.